scispace - formally typeset
P

Peter J. Schüffler

Researcher at Memorial Sloan Kettering Cancer Center

Publications -  64
Citations -  2781

Peter J. Schüffler is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Digital pathology & Medicine. The author has an hindex of 21, co-authored 54 publications receiving 2069 citations. Previous affiliations of Peter J. Schüffler include University of Zurich & Technische Universität München.

Papers
More filters
Journal ArticleDOI

Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry

TL;DR: The coupled immunohistochemical and immunocytochemical methods with high-resolution laser ablation to CyTOF mass cytometry enables the simultaneous imaging of 32 proteins and protein modifications at subcellular resolution and complements existing imaging approaches.
Journal ArticleDOI

Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer

TL;DR: A two-stage strategy for the discovery of serum biomarker signatures corresponding to specific cancer-causing mutations and its application to prostate cancer (PCa) in the context of the commonly occurring phosphatase and tensin homolog (PTEN) tumor-suppressor gene inactivation.
Journal ArticleDOI

Whole slide imaging equivalency and efficiency study: experience at a large academic center.

TL;DR: This randomized, equivalency and efficiency study aimed to replicate clinical workflow, comparing conventional microscopy to a complete digital pathology signout using whole slide images, evaluating the equivalencies and efficiency of glass slide to whole slide image reporting, reflective of true pathology practice workloads in the clinical setting.
Journal ArticleDOI

Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer

TL;DR: Although the Wnt antagonist genes WIF1 and DKK3 show a very similar frequency of promoter methylation in human breast cancer, only DKK 3 methylation proves as a novel prognostic marker potentially useful in the clinical management of this disease.